Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 2, 2009, Pages 172-179

  Park, Eun Kyung ^a   Chung, June Key ^a   Lim, Il Han ^a   Park, Do Joon ^a   Lee, Dong Soo ^a   Lee, Myung Chul ^a   Cho, Bo Youn ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Differentiated thyroid carcinoma; I 131 whole body scan; Metastasis; Recurrence; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ADULT; ARTICLE; CANCER REGRESSION; CANCER STAGING; DISTANT METASTASIS; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HUMAN; IMMUNORADIOMETRIC ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; RADIOIMMUNOASSAY; RADIOISOTOPE THERAPY; RECURRENT CANCER; STATISTICAL ANALYSIS; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADULT; FALSE NEGATIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RECURRENCE; THYROGLOBULIN; THYROID NEOPLASMS; WHOLE BODY IMAGING;

EID: 58849084983     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0912-0     Document Type: Article

References (30)

1. M Saghari A Gholamrezanezhad S Mirpour M Eftekhari A Takavar A Fard-Esfahani 2006 Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan Nucl Med Commun 27 567 572
2. MJ Schlumberger 1999 Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status J Endocrinol Invest 22 3 7
3. EL Mazzaferri RT Kloos 2000 Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions Thyroid 10 767 778
4. J Nemec S Rohling V Zamrazil D Pohunkova 1979 Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers J Nucl Med 20 92 97
5. BW Lee DS Lee DH Moon JK Chung MC Lee BY Cho 1990 Comparison of I-131 diagnostic scan and therapeutic scan in thyroid carcinoma Korean J Nucl Med 24 80 86
6. EL Mazzaferri RJ Robbins CA Spencer LE Braverman F Pacini L Wartofsky 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma J Clin Endocrinol Metab 88 1433 1441
7. L Pagano M Klain M Pulcrano G Angellotti F Pasano M Salvatore 2004 Follow-up of differentiated thyroid carcinoma Minerva Endocrinol 29 161 174
8. M Schlumberger G Berg O Cohen L Duntas F Jamar B Jarzab 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective Eur J Endocrinol 150 105 112
9. F Pacini M Schlumberger H Dralle R Elisei JW Smit W Wiersinga 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Eur J Endocrinol 154 787 803
10. G Pellegriti C Scollo C Regalbuto M Attard P Marozzi F Vermiglio 2003 The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels Clin Endocrinol (Oxf) 58 556 561
11. C Ma A Kuang J Xie T Ma 2005 Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning J Nucl Med 46 1473 1480
12. S Mariotti C Cupini C Giani R Lari E Rolleri A Falco 1982 Evaluation of a solid-phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of anti-thyroglobulin autoantibody Clin Chim Acta 123 347 355
13. D Rubello ME Girelli D Casara M Piccolo A Perin B Busnardo 1990 Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer J Endocrinol Invest 13 737 742
14. R Schulz H Bethauser L Stempka B Heilig A Moll M Hufner 1989 Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men Eur J Clin Invest 19 459 463
15. HW Muller-Gartner C Schneider 1988 Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer Cancer 61 976 981
16. IJ Mertens JM De Klerk PM Zelissen JH Thijssen DM Sie-Go SH Han 1999 Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer Clin Nucl Med 24 346 349
17. AJ Brendel B Lambert M Guyot R Jeandot H Dubourg P Roger 1990 Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma Eur J Nucl Med 16 35 38
18. S Grant B Luttrell T Reeve J Wiseman E Wilmshurst J Stiel 1984 Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma Cancer 54 1625 1628
19. NG Morgenthaler J Froehlich J Rendl M Willnich C Alonso A Bergmann 2002 Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin Clin Chem 48 1077 1083
20. A Bachelot AF Cailleux M Klain E Baudin M Ricard N Bellon 2002 Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma Thyroid 12 707 711
21. K Pazaitou-Panayiotou M Capezzone F Pacini 2007 Clinical features and therapeutic implication of papillary thyroid microcarcinoma Thyroid 17 1085 1092
22. N Wada QY Duh K Sugino H Iwasaki K Kameyama T Mimura 2003 Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection Ann Surg 237 399 407
23. G Ronga M Filesi G Ventroni AR Vestri A Signore 1999 Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma Eur J Nucl Med 26 1448 1452
24. DH Shah SR Dandekar RK Jeevanram A Kumar SM Sharma RD Ganatra 1981 Serum thyroglobulin differentiated thyroid carcinoma: histological and metastatic classification Acta Endocrinol (Copenh) 98 222 226
25. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning J Clin Endocrinol Metab 86 5294 5300
26. M Urhan S Dadparvar A Mavi M Houseni W Chamroonrat A Alavi 2007 Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement Eur J Nucl Med Mol Imaging 34 1012 1017
27. E Rault S Vandenberghe R Van Holen J De Beenhouwer S Staelens I Lemahieu 2007 Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131) Cancer Biother Radiopharm 22 423 430
28. SM Larson R Robbins 2002 Positron emission tomography in thyroid cancer management Semin Roentgenol 37 169 174
29. A Iervasi G Iervasi A Bottoni G Boni C Annicchiarico P Di Cecco 2004 Diagnostic performance of a new highly sensitive thyroglobulin immunoassay J Endocrinol 182 287 294
30. CA Spencer JS LoPresti S Fatemi JT Nicoloff 1999 Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement Thyroid 9 435 441